Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Nat Rev Clin Oncol. 2022 May 9. doi: 10.1038/s41571-022-00639-9. Online ahead of print.
Nat Rev Clin Oncol. 2022.
PMID: 35534623
Review.